Cardax, Inc. (OTCPK: CDXI)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Cardax, Inc. (OTCPK: CDXI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.00 and employs 10 people.
trading between 0.00 and 0.00.
Tweenvest scores Cardax, Inc. across four factors: quality 6/100, value 46/100. Its strongest factor is value.
CDXI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.00
- Revenue (TTM)
- $500.71K
- P/E
- —
- EPS
- -6.77
- Dividend yield
- —
- Beta (5Y)
- 27.91
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 825.18K
- Employees
- 10
- Next earnings
- —
About Cardax, Inc.
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currently under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.
- ISIN
- US14141D2018
- Listed since
- Mar 6, 2013
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.20 | +0.12% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.56 | +0.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.26 | -0.12% |
| Roche Holding AGSWX: ROP | $371.62B | CHF374.20 | +0.11% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.68 | -0.87% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.